ENTRY       D09214                      Drug
NAME        Ustekinumab (USAN/INN);
            Ustekinumab (genetical recombination) (JAN);
            Ustekinumab (genetical recombination) [Ustekinumab biosimilar 1] (JAN);
            Stelara (TN)
PRODUCT     STELARA (Janssen Biotech)
FORMULA     C6482H10004N1712O2016S46
EXACT_MASS  145556.0074
MOL_WEIGHT  145646.04
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC05
            Product: D09214<JP/US>
EFFICACY    Antipsoriatic, Anti-IL12/IL23 antibody
  DISEASE   Psoriasis [DS:H01656]
            Psoriatic arthritis [DS:H01507]
            Crohn's disease [DS:H00286]
            Ulcerative colitis [DS:H01466]
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      IL12 [HSA:3592 3593] [KO:K05406 K05425]
            IL23A [HSA:51561] [KO:K05426]
  PATHWAY   hsa04060(3592+3593+51561)  Cytokine-cytokine receptor interaction
            hsa04630(3592+3593+51561)  JAK-STAT signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC05 Ustekinumab
                  D09214  Ustekinumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Ustekinumab
                 D09214  Ustekinumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D09214  Ustekinumab (USAN/INN); Ustekinumab (genetical recombination) (JAN); Ustekinumab (genetical recombination) [Ustekinumab biosimilar 1] (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09214  Ustekinumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09214  Ustekinumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL12
                 D09214  Ustekinumab (USAN/INN) &lt;JP/US&gt;
                IL23A
                 D09214  Ustekinumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09214
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09214
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09214
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09214
DBLINKS     CAS: 815610-63-0
            PubChem: 96025894
///
